Methods to produce mRNA-based human healthcare products have been in development since the mid-'90s. However, the rapid deployment and strong product profile of the SARS-CoV-2 vaccines has initiated a turning point for this new technology, said NTx in a press release. Recent experience with the COVID-19 vaccines has highlighted constrained capacity and relatively high production costs that have limited patient access, particularly in low- and middle-income countries.

NTx is a bioinformatics and biomanufacturing company advancing cell-free, continuous-flow manufacturing solutions for medical products and material sciences. NTx is commercializing cell-free, continuous-flow manufacturing for mRNA and protein-based medical products. The purpose behind the increased development of this technology is to speed the delivery of innovative medicines to patients and improve global supply chains.